206 related articles for article (PubMed ID: 25128047)
1. A framework to evaluate the cost-effectiveness of the NADiA ProsVue slope to guide adjuvant radiotherapy among men with high-risk characteristics following prostatectomy for prostate cancer.
Reed SD; Stewart SB; Scales CD; Moul JW
Value Health; 2014 Jul; 17(5):545-54. PubMed ID: 25128047
[TBL] [Abstract][Full Text] [Related]
2. NADiA ProsVue prostate-specific antigen slope, CAPRA-S, and prostate cancer--specific survival after radical prostatectomy.
Moul JW; Sarno MJ; McDermed JE; Triebell MT; Reynolds MA
Urology; 2014 Dec; 84(6):1427-32. PubMed ID: 25432832
[TBL] [Abstract][Full Text] [Related]
3. Impact of NADiA ProsVue PSA slope on secondary treatment decisions after radical prostatectomy.
Moul JW; Chen DY; Trabulsi EJ; Warlick CA; Ruckle HC; Porter JR; Yoshida JS; Adams GW; Kella N; Matsunaga GS; Bans LL; Sarno MJ; McDermed JE; Triebell MT; Reynolds MA;
Prostate Cancer Prostatic Dis; 2014 Sep; 17(3):280-5. PubMed ID: 25027863
[TBL] [Abstract][Full Text] [Related]
4. NADiA ProsVue prostate-specific antigen slope is an independent prognostic marker for identifying men at reduced risk of clinical recurrence of prostate cancer after radical prostatectomy.
Moul JW; Lilja H; Semmes OJ; Lance RS; Vessella RL; Fleisher M; Mazzola C; Sarno MJ; Stevens B; Klem RE; McDermed JE; Triebell MT; Adams TH
Urology; 2012 Dec; 80(6):1319-25. PubMed ID: 23107099
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of risk-prediction tools in selecting patients for immediate post-prostatectomy treatment.
Zubek VB; Konski A
Mol Diagn Ther; 2009; 13(1):31-47. PubMed ID: 19351214
[TBL] [Abstract][Full Text] [Related]
6. A decision support model for cost-effectiveness of radical prostatectomy in localized prostate cancer.
Lyth J; Andersson SO; Andrén O; Johansson JE; Carlsson P; Shahsavar N
Scand J Urol Nephrol; 2012 Feb; 46(1):19-25. PubMed ID: 21905981
[TBL] [Abstract][Full Text] [Related]
7. Patterns and predictors of early biochemical recurrence after radical prostatectomy and adjuvant radiation therapy in men with pT3N0 prostate cancer: implications for multimodal therapies.
Briganti A; Joniau S; Gandaglia G; Cozzarini C; Sun M; Tombal B; Haustermans K; Hinkelbein W; Shariat SF; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):960-7. PubMed ID: 24351411
[TBL] [Abstract][Full Text] [Related]
8. A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy -- Adjuvant Versus Early Salvage (RAVES) trial.
Pearse M; Fraser-Browne C; Davis ID; Duchesne GM; Fisher R; Frydenberg M; Haworth A; Jose C; Joseph DJ; Lim TS; Matthews J; Millar J; Sidhom M; Spry NA; Tang CI; Turner S; Williams SG; Wiltshire K; Woo HH; Kneebone A
BJU Int; 2014 Mar; 113 Suppl 2():7-12. PubMed ID: 24894850
[TBL] [Abstract][Full Text] [Related]
9. Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis.
Briganti A; Wiegel T; Joniau S; Cozzarini C; Bianchi M; Sun M; Tombal B; Haustermans K; Budiharto T; Hinkelbein W; Di Muzio N; Karakiewicz PI; Montorsi F; Van Poppel H
Eur Urol; 2012 Sep; 62(3):472-87. PubMed ID: 22633803
[TBL] [Abstract][Full Text] [Related]
10. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
11. Primary radiotherapy versus radical prostatectomy for high-risk prostate cancer: a decision analysis.
Parikh R; Sher DJ
Cancer; 2012 Jan; 118(1):258-67. PubMed ID: 21720990
[TBL] [Abstract][Full Text] [Related]
12. Comparative analysis of three risk assessment tools in Australian patients with prostate cancer.
Tamblyn DJ; Chopra S; Yu C; Kattan MW; Pinnock C; Kopsaftis T
BJU Int; 2011 Nov; 108 Suppl 2():51-6. PubMed ID: 22085129
[TBL] [Abstract][Full Text] [Related]
13. Multi-institutional validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy.
Punnen S; Freedland SJ; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Carroll PR; Cooperberg MR
Eur Urol; 2014 Jun; 65(6):1171-7. PubMed ID: 23587869
[TBL] [Abstract][Full Text] [Related]
14. Risk stratification of patients with extraprostatic extension and negative lymph nodes at radical prostatectomy: identifying optimal candidates for adjuvant therapy.
Eisenberg MS; Karnes RJ; Kaushik D; Rangel L; Bergstralh EJ; Boorjian SA
J Urol; 2013 Nov; 190(5):1735-41. PubMed ID: 23727312
[TBL] [Abstract][Full Text] [Related]
15. Maximum tumor diameter and the risk of prostate-specific antigen recurrence after radical prostatectomy.
Rose BS; Chen MH; Zhang D; Hirsch MS; Richie JP; Chang SL; Hegde JV; Loffredo MJ; D'Amico AV
Clin Genitourin Cancer; 2014 Oct; 12(5):e173-9. PubMed ID: 24787967
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of adjuvant radiotherapy in intermediate risk endometrial cancer.
Rankins NC; Secord AA; Jewell E; Havrilesky LJ; Soper JT; Myers E
Gynecol Oncol; 2007 Aug; 106(2):388-93. PubMed ID: 17509672
[TBL] [Abstract][Full Text] [Related]
17. Importance of margin extent as a predictor of outcome after adjuvant radiotherapy for Gleason score 7 pT3N0 prostate cancer.
Valicenti RK; Chervoneva I; Gomella LG
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1093-7. PubMed ID: 15001249
[TBL] [Abstract][Full Text] [Related]
18. Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE.
Mitchell JA; Cooperberg MR; Elkin EP; Lubeck DP; Mehta SS; Kane CJ; Carroll PR
J Urol; 2005 Apr; 173(4):1126-31. PubMed ID: 15758720
[TBL] [Abstract][Full Text] [Related]
19. High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy.
Savdie R; Horvath LG; Benito RP; Rasiah KK; Haynes AM; Chatfield M; Stricker PD; Turner JJ; Delprado W; Henshall SM; Sutherland RL; Kench JG
BJU Int; 2012 Jun; 109(12):1794-800. PubMed ID: 21992536
[TBL] [Abstract][Full Text] [Related]
20. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
May M; Knoll N; Siegsmund M; Fahlenkamp D; Vogler H; Hoschke B; Gralla O
J Urol; 2007 Nov; 178(5):1957-62; discussion 1962. PubMed ID: 17868719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
